Literature DB >> 16185172

Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.

James F Graumlich1, Saba Habis, Rosario R Avelino, Sandra M Salverson, Madhavi Gaddamanugu, Kiranmai Jamma, Jean C Aldag.   

Abstract

STUDY
OBJECTIVES: To compare the incidence of hypoglycemic events in patients exposed to gatifloxacin or levofloxacin, and to measure the odds of experiencing a hypoglycemic event after receiving gatifloxacin versus levofloxacin while adjusting for confounders.
DESIGN: Nested case-control study within a historical cohort.
SETTING: A tertiary care, 730-bed, teaching hospital in central Illinois. PATIENTS: Seven thousand two hundred eighty-seven hospitalized patients who received gatifloxacin or levofloxacin therapy.
MEASUREMENTS AND MAIN RESULTS: A total of 113 patients (case patients) had blood glucose levels below 51 mg/dl; 113 control patients, matched for age and sex, had no hypoglycemia. Matched conditional logistic regression models adjusted the odds of having hypoglycemia for significant covariates. The 12-month incidence of hypoglycemia was 11/1000 patients after levofloxacin administration and 21/1000 patients after gatifloxacin (absolute risk increase 10/1000 patients, 95% confidence interval [CI] 4-16/1000). Renal failure, sepsis syndrome, and concomitant hypoglycemic drug therapy significantly predicted hypoglycemia. After adjustment for significant predictors, the odds of having hypoglycemia were 2.81 (95% CI 1.02-7.70) times higher after gatifloxacin than levofloxacin therapy.
CONCLUSION: Among inpatients, the incidence of hypoglycemic events is greater after treatment with gatifloxacin than levofloxacin. The odds of experiencing hypoglycemic events are greater with gatifloxacin even after adjusting for other hypoglycemia risk factors, such as concomitant hypoglycemic drugs, renal failure, and sepsis syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185172     DOI: 10.1592/phco.2005.25.10.1296

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

2.  An evaluation of the effects of gatifloxacin on glucose homeostasis.

Authors:  Ahunna J Onyenwenyi; Almut G Winterstein; Randy C Hatton
Journal:  Pharm World Sci       Date:  2008-02-23

Review 3.  Dysglycaemias and fluoroquinolones.

Authors:  Roshan J Lewis; John F Mohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia.

Authors:  Wissam K Kabbara; Wijdan H Ramadan; Peggy Rahbany; Souhaila Al-Natour
Journal:  Ther Clin Risk Manag       Date:  2015-04-22       Impact factor: 2.423

6.  Severe and Recurrent Hypoglycemia Caused by Garenoxacin in a Patient not Taking Hypoglycemic Drugs.

Authors:  Manabu Kondo; Yuka Miyoshi; Kohji Tarumoto; Norie Hirayama; Takahiro Sasaki; Kohji Yamashita; Susumu Yamashita; Katsuhiro Hatao
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

Review 7.  How Safe are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones.

Authors:  Abdulrhman Althaqafi; Long Chiau Ming; Majid Ali; Yusuf Alzahrani; Zahid Hussain
Journal:  Ther Clin Risk Manag       Date:  2021-10-13       Impact factor: 2.423

8.  Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia.

Authors:  S Vallurupalli; G Huesmann; J Gregory; M G Jakoby
Journal:  Diabet Med       Date:  2008-07       Impact factor: 4.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.